Immunologic Privilege in the Central Nervous System and the Blood–Brain Barrier. Issue 1 (January 2013)

• Record Type: Journal Article
• Authors: Muldoon, Leslie L; Alvarez, Jorge I; Begley, David J; Boado, Ruben J; del Zoppo, Gregory J; Doolittle, Nancy D; Engelhardt, Britta; Hallenbeck, John M; Lonser, Russell R; Ohlfest, John R; Prat, Alexandre; Scarpa, Maurizio; Smeyne, Richard J; Drewes, Lester R; Neuwelt, Edward A
• Is Part Of: Journal of cerebral blood flow & metabolism. Volume 33:Issue 1(2013)
• Page Start: 13
• Page End: 21
• Publication Date: 2013-01
• Subjects: blood–brain barrier -- multiple sclerosis -- neuroimaging -- neuroinflammation -- neurovascular unit; Cerebral circulation -- Periodicals; Brain -- Metabolism -- Periodicals; Brain -- Blood-vessels -- Periodicals; Cerebrovascular disease -- Periodicals; 612.824
• DOI: 10.1038/jcbfm.2012.153
• Languages: English
• ISSNs: 0271-678X

Abstract

The brain is in many ways an immunologically and pharmacologically privileged site. The blood–brain barrier (BBB) of the cerebrovascular endothelium and its participation in the complex structure of the neurovascular unit (NVU) restrict access of immune cells and immune mediators to the central nervous system (CNS). In pathologic conditions, very well-organized immunologic responses can develop within the CNS, raising important questions about the real nature and the intrinsic and extrinsic regulation of this immune privilege. We assess the interactions of immune cells and immune mediators with the BBB and NVU in neurologic disease, cerebrovascular disease, and intracerebral tumors. The goals of this review are to outline key scientific advances and the status of the science central to both the neuroinflammation and CNS barriers fields, and highlight the opportunities and priorities in advancing brain barriers research in the context of the larger immunology and neuroscience disciplines. This review article was developed from reports presented at the 2011 Annual Blood-Brain Barrier Consortium Meeting.